iCo Therapeutics (iCo Therapeutics) Interest Expense : $0.00 Mil (TTM As of Mar. 2021)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. iCo Therapeutics's interest expense for the three months ended in Mar. 2021 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. iCo Therapeutics's Operating Income for the three months ended in Mar. 2021 was $ -0.62 Mil. iCo Therapeutics's Interest Expense for the three months ended in Mar. 2021 was $ 0.00 Mil. iCo Therapeutics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

iCo Therapeutics Interest Expense Historical Data

The historical data trend for iCo Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics Interest Expense Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Interest Expense

Get a 7-Day Free Trial

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

iCo Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

iCo Therapeutics (GREY:ICOTF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

iCo Therapeutics's Interest Expense for the three months ended in Mar. 2021 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2021 was $-0.62 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2021 was $0.00 Mil.

iCo Therapeutics's Interest Coverage for the quarter that ended in Mar. 2021 is calculated as

iCo Therapeutics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

iCo Therapeutics Inc has no debt.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines